Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment of Adolescent Suicide Attempters (TASA)

This study has been completed.
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
New York State Psychiatric Institute Identifier:
First received: March 24, 2004
Last updated: November 1, 2013
Last verified: July 2008
The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Condition Intervention Phase
Suicide, Attempted
Drug: fluoxetine
Drug: sertraline
Drug: citalopram
Drug: escitalopram
Drug: bupropion
Drug: mirtazapine
Drug: venlafaxine
Drug: lithium
Behavioral: Cognitive Behavioral Therapy
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by New York State Psychiatric Institute:

Estimated Enrollment: 120
Study Start Date: March 2004
Study Completion Date: June 2007
Detailed Description:

Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.

Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.


Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least one suicide attempt or interrupted attempt within the past 45 days
  • Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00080158

United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, New York
New York University Child Study Center
New York, New York, United States, 10016
Columbia University at the New York State Psychiatric Institute
New York, New York, United States, 10032
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
United States, Pennsylvania
University of Pittsburgh - Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
University of Texas, Southwestern Medical Center
Dallas, Texas, United States, 75235
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)
Study Chair: Laurence Greenhill, MD
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: New York State Psychiatric Institute Identifier: NCT00080158     History of Changes
Obsolete Identifiers: NCT00183534
Other Study ID Numbers: #4623  U10MH066762  U10MH066775  U10MH066778  U10MH066769  U10MH066750  DDTR B4-ARD 
Study First Received: March 24, 2004
Last Updated: November 1, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by New York State Psychiatric Institute:
Dysthymic Disorder

Additional relevant MeSH terms:
Suicide, Attempted
Self-Injurious Behavior
Behavioral Symptoms
Venlafaxine Hydrochloride
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Serotonin Agents
Antidepressive Agents, Second-Generation
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on October 26, 2016